Virus-induced asthma: possible prevention and treatment

Cover Page

Cite item

Full Text

Abstract

Most patients suffering from bronchial asthma achieved disease control as a result of therapy with inhaled corticosteroids and b2-agonists, but these drugs may be ineffective in the treatment of virus-induced asthma exacerbations. Respiratory viral infections are the most common cause of broncho-obstructive syndrome in young children and the most frequent triggers of asthmatic exacerbations in children, adolescents and adults. This article discusses the relationship of respiratory viruses and allergens, causes of virus-induced asthma exacerbations, as well as the role of antileukotriene drugs in the treatment of asthma and prevention of virus-induced exacerbations.

About the authors

N. M Nenasheva

Russian Medical Academy for Postgraduate Education of the Ministry of Health of the Russian Federation

Email: rmapo@rmapo.ru
д-р мед. наук, проф. каф. клин. аллергологии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1

References

  1. Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». IV издание. М., 2012.
  2. Chuchalin A, Khaltaev N, Antonov N et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD 2014; 9: 963-74.
  3. GINA 2015. ginasthma.org
  4. Reddel H, Ware S, Marks G et al. Differences between asthma exacerbations and poor asthma control. Lancet 1999; 353: 364-9.
  5. Sigurs N, Gustafsson P.M, Bjarnason R et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 171 (2): 137-41, 2005.
  6. Sigurs N, Aljassim F, Kjellman B et al. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 2010; 65 (12): 1045-52.
  7. Weiss S.T, Tager I.B, Munoz A et al. The relationship of respiratory infections in early childhood to the occurrence of increased levels of bronchial responsiveness and atopy. Am Rev Respir Dis 1985; 131 (4): 573-8.
  8. Stein R, Sherrill D, Morgan W.J et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 354 (9178): 541-5.
  9. Szabo S.M, Levy A.R, Gooch K.L et al. Elevated risk of asthma after hospitalization for respiratory syncytial virus infection in infancy. Paediatr Respir Rev 2013; 13 (Suppl. 2): S9-S15.
  10. Stein R.T. Long - term airway morbidity following viral LRTI in early infancy: recurrent wheezing or asthma? Paediatr Respir Rev 2009; 10 (Suppl 1): 29-31.
  11. Kusel M.M, de Klerk N.H, Kebadze T et al. Early - life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol 2007; 119 (5): 1105-10.
  12. Takeyama A, Hashimoto K, Sato M et al. Clinical and epidemiologic factors related to subsequent wheezing after virus - induced lower respiratory tract infections in hospitalized pediatric patients younger than 3 years. Eur J Pediatr 2014; 173: 959-66.
  13. O’Callaghan-Gordo C, Bassat Q, Diez-Padrisa N et al. Lower respiratory tract infections associated with rhinovirus during infancy and increased risk of wheezing during childhood. A cohort study. PLoS One 2013; 8 (7): e69370. doi: 10.1371/journal.pone.0069370
  14. Jackson D.J, Gangnon R.E, Evans M.D et al. Wheezing rhinovirus illnesses in early life predict asthma development in high - risk children. Am J Respir Crit Care Med 2008; 178: 667-72.
  15. Sly P.D, Boner A.L, Bjorksten B et al. Earlyidentification of atopy in the predictionof persistent asthma in children. Lancet 2008; 372: 1100-6.
  16. Woodruff P, Bhakta N, Fahy J. Asthma: Pathogenesis and Phentoypes. In: Murray and Nadel’s textbook of respiratory medicine. 6-th Edition, printed of Elsevier Inc., 2016; p. 713-30.
  17. Martinez F.D, Wright A.L, Taussig L.M et al. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. N Engl J Med 1995; 332 (3): 133-8.
  18. Martinez F.D, Stern D.A, Wright A.L et al. Differential immune responses to acute lower respiratory illness in early life and subsequent development of persistent wheezing and asthma. J Allergy Clin Immunol 1998; 102 (6 Pt 1): 915-20.
  19. Soto-Quiros M, Avila L, Platts-Mills T et al. High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. J Allergy Clin Immunol 2012; 129: 1499-505.
  20. Macaubas C, de Klerk N.H, Holt B.J et al. Association between antenatal cytokine production and the development of atopy and asthma at age 6 years. Lancet 2003; 362: 1192-7.
  21. Johnston N.W, Johnston S.L, Duncan J.M et al. The September epidemic of asthma exacerbations in children: a search for etiology. J Allergy Clin Immunol 2005; 115: 132-8.
  22. Longini I.M, Monto A.S, Koopman J.S. Statistical procedures for esti - mating the community probability of illness in family studies: rhinovirus and influenza. Int J Epidemiol 1984; 13: 99-106.
  23. Freymuth F, Vabret A, Brouard J et al. Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children. J Clin Virol 1999; 13: 131-9.
  24. Nicholson K.G, Kent J, Ireland D.C. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993; 307: 982-6.
  25. Teichtahl H, Buckmaster N, Pertnikovs E. The incidence of respiratory tract infection in adults requiring hospitalization for asthma. Chest 1997; 112: 591-6.
  26. Atmar R.L, Guy E, Guntupalli K.K et al. Respiratory tract viral infections in inner - city asthmatic adults. Arch Intern Med 1998; 158: 2453-9.
  27. Дзюблик А.Я., Симонов С.С., Ячник В.А. Клиническая эффективность и безопасность противовирусного препарата Ингавирин в комплексном лечении больных с обострением бронхиальной астмы, ассоциированным с ОРВИ. Пульмонология. 2013; 6: 43-50.
  28. Message S.D, Laza-Stanca V, Mallia P et al. Rhinovirus - induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A 2008; 105: 13562-7.
  29. Green R.M, Custovic A, Sanderson G et al. Synergism between allergens and viruses and risk of hospital admission with asthma: case - control study. BMJ 2002; 324: 763.
  30. Busse W.W, Morgan W.J, Gergen P.J et al. Randomized trial of omalizumab (anti - IgE) for asthma in inner - city children. N Engl J Med 2011; 364: 1005-15.
  31. Bui R.H, Molinaro G.A, Kettering J.D et al. Virus - specific IgE and IgG4 antibodies in serum of children infected with respiratory syncytial virus. J Pediatr 1987; 110: 87-90.
  32. Rabatic S, Gagro A, Lokar-Kolbas R et al. Increase in CD23+ B cells in infants with bronchiolitis is accompanied by appearance of IgE and IgG4 antibodies specific for respiratory syncytial virus. J Infect Dis 1997; 175: 32-7.
  33. Cheung D.S, Ehlenbach S.J, Kitchens R.T et al. Cutting edge: CD49d+ neutrophils induce FcepsilonRI expression on lung dendritic cells in a mouse model of postviral asthma. J Immunol. 2010; 185: 4983-7.
  34. Stephens R, Randolph D.A, Huang G et al. Antigen - nonspecific recruitment of Th2 cells to the lung as a mechanism for viral infection - induced allergic asthma. J Immunol 2002; 169: 5458-67.
  35. Cheung D.S, Ehlenbach S.J, Kitchens T et al. Development of atopy by severe paramyxoviral infection in a mouse model. Ann Allergy Asthma Immunol 2010; 105: 437-43.
  36. Cheung D.S, Grayson M.H. Role of Viruses in the Development of Atopic Disease in Pediatric Patients. Curr Allergy Asthma Rep 2012. doi: 10.1007/s11882-012-0295-y
  37. Al-Garawi A.A, Fattouh R, Walker T.D et al. Acute, but not resolved, influenza A infection enhances susceptibility to house dust mite - induced allergic disease. J Immunol 2009; 182: 3095-104.
  38. Durrani S.R, Montville D.J, Pratt A.S et al. Innate immune responses to rhinovirus are reduced by the high - affinity IgE receptor in allergic asthmatic children. J Allergy Clin Immunol 2012; 130: 489-95.
  39. Holtzman M.J. Asthma as a chronic disease of the innate and adaptive immune systems responding to viruses and allergens. J Clin Invest 2012; 122 (8): 2741-8.
  40. Gavala M.L, Bertics P.J, Gern J.E. Rhinoviruses, allegic inflammation and asthma. Immunol Rev 2011; 242 (1): 69-90.
  41. Wark P.A, Johnston S.L, Bucchieri F et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005; 201 (6): 937-47.
  42. Contoli M, Message S.D, Laza-Stanca V et al. Role of deficient type III interferon - lambda production in asthma exacerbations. Nat Med 2006; 12 (9): 1023-6.
  43. Lopez-Souza N, Favoreto S, Wong H et al. In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects. J Allergy Clin Immunol 2009; 123 (6): 1384-90 e2.
  44. Schwantes E, Denlinger L, Evans M et al. Severity of virus - induced asthma symptoms is inversely related to resolution IFN-l expression. J Allergy Clin Immunol 2015; 135 (6): 1656-9.
  45. Shadman K.A, Wald E.R. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther 2011; 11 (11): 1455-67.
  46. Simoes E.A, Groothuis J.R, Carbonell-Estrany X et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007; 151: 34-42. 42 e31.
  47. Suissa S, Ernst P, Benayoun S et al. Low - dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332-6.
  48. O’Byrne P.M, Barnes P.J, Rodriguez-Roisin R et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-7.
  49. Matz J, Emmett A, Rickard K et al. Addition of salmeterol to low - dose fluticasone versus higher - dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol 2001; 107: 783-9.
  50. Prazma C, Kral K, Gul N et al. Controller medications and their effects on asthma exacerbations temporally associated with upper respiratory infections. Respir Med 2010; 104: 780-7.
  51. Walter M.J, Castro M, Kunselman S.J et al. Predicting worsening asthma control following the common cold. Eur Respir J 2008; 32: 1548-54.
  52. Wark P.A, Grissell T, Davies B et al. Diversity in the bronchial epithelial cell response to infection with different rhinovirus strains. Respirology 2009; 14: 180-6.
  53. Calvo C, Garcia M.L, Pozo F et al. Role of rhinovirus C in apparently life - threatening events in infants, Spain. Emerg Infect Dis 2009; 15: 1506-8.
  54. Çalışkan M, Bochkov Y, Kreiner-Møller E et al. Rhinovirus Wheezing Illness and Genetic Risk of Childhood-Onset Asthma. N Engl J Med 2013; 368: 1398-407.
  55. Van Ly D, King N.J, Moir L.M et al. Effects of b2 agonists, corticosteroids, and novel therapies on rhinovirus - induced cytokine release and rhinovirus replication in primary airway fibroblasts. J Allergy 2011; 2011: 457169.
  56. Tacon C.E, Newton R, Proud D et al. Rhinovirus - induced MMP-9 expression is dependent on Fra-1, which is modulated by formoterol and dexamethasone. J Immunol 2012; 188: 4621-30.
  57. Papi A, Contoli M, Adcock I et al. Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor kB and c-Jun N-terminal kinase activation. J Allergy Clin Immunol 2013; 132: 1075-85.
  58. Gruunberg K, Sharon R.F, Sont J.K et al. Rhinovirus - induced airway inflammation in asthma. Am J Respir Crit Care Med 2001; 164: 1816-22.
  59. Grunberg K, Sharon R.F, Hiltermann T.J et al. Experimental rhinovirus 16 infection increases intercellular adhesion molecule-1 expression in bronchial epithelium of asthmatics regardless of inhaled steroid treatment. Clin Exp Allergy 2000; 30: 1015-23.
  60. Gustafson L, Proud D, Hendley J et al. Oral prednisone therapy in experimental rhinovirus infections. J Allergy Clin Immunol 1996; 97: 1009-14.
  61. Farr B.M, Gwaltney J.M, Hendley J.O et al. Randomized controlled trial of glucocorticoid prophylaxis against experimental rhinovirus infection. J Infect Dis 1990; 162: 1173-7.
  62. Harrison T.W, Oborne J, Newton S et al. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004; 363: 271-5.
  63. Fitz-Gerald J.M, Becker A, Sears M.R et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550-6.
  64. Oborne J, Mortimer K, Hubbard R.B et al. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double - blind, placebo - controlled, parallel - group clinical trial. Am J Respir Crit Care Med 2009; 180: 598-602.
  65. Ducharme F.M, Lemire C, Noya F.J et al. Preemptive use of high - dose fluticasone for virus - induced wheezing in young children. N Engl J Med 2009; 360: 339-53.
  66. Oliver B, Robinson P, Peters M, Black J. Viral infections and asthma:an inflammatory interface? Eur Respir J 2014; 44: 1666-81.
  67. Van Ly D, Faiz A, Jenkins C et al. Characterising the mechanism of airway smooth muscle b2 adrenoceptor desensitization by rhinovirus infected bronchial epithelial cells. PLoS One 2013; 8: e56058.
  68. Wos M, Sanak M, Soja J et al. The presence of rhinovirus in lower airways of patients with bronchial asthma. Am J Respir Crit Care Med 2008; 177: 1082-9.
  69. Peters-Golden M, Henderson W.R. Leukotrienes. N Engl J Med 2007; 357: 1841-54.
  70. Busse W, Kraft M. Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. Chest 2005; 127: 1312-26.
  71. Hallstrand T.S, Henderson W.R.Jr. An update on the role of leukotrienes in asthma. Curr Opin Allergy Clin Immunol 2010; 10: 60-6.
  72. Mehrotra A.K, Henderson W.R.Jr. The role of leukotrienes in airway remodeling. Curr Mol Med 2009; 9: 383-91.
  73. Mc Carthy M, Weinberg J. Eicosanoids and Respiratory Viral Infection: Coordinators of Inflammation and Potential Therapeutic Targets. Mediat Inflamm 2012, Article ID 236345.
  74. Seymour M.L, Gilby N, Bardin P.G et al. Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from nonatopic subjects. J Infect Dis 2002; 185: 540-4.
  75. Gentile D.A, Fireman P, Skoner D.P. Elevations of local leukotriene C4 levels during viral upper respiratory tract infections. Ann Allergy Asthma Immunol 2003; 91: 270-4.
  76. Matsuse H, Hirose H, Tsuchida T et al. Effects of respiratory syncytial virus infection on dendritic cells and cysteinyl leukotrienes in lung tissues of a murine model of asthma. Allergol Int 2007; 56: 165-9.
  77. van Schaik S.M, Tristram D.A, Nagpal I.S et al. Increased production of IFN-gamma and cysteinyl leukotrienes in virus - induced wheezing. J Allergy Clin Immunol 1999; 103: 630-6.
  78. Wedde-Beer K, Hu C, Rodriguez M.M, Piedimonte G. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol 2002; 282: L1143 (L1L50).
  79. Amrani Y, Moore P.E, Hoffman R et al. Interferon - gamma modulates cysteinyl leukotriene receptor-1 expression and function in human airway myocytes. Respir Crit Care Med 2001; 164: 2098-101.
  80. Fey C, Thyroff-Friesinger U, Jones S. Bioequivalence of two formulations of montelukast sodium 4 mg oral granules in healthy adults. Clin Transl Allergy 2014; 4: 29.
  81. Barnes N.C, Miller C.J. Effect of leukotriene receptor antagonist therapy on therisk of asthma exacerbations in patients with mild to moderate asthma: an integratedanalysis of zafirlukast trials. Thorax 2000; 55: 478-83.
  82. Johnston N.W, Mandhane P.J, Dai J et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007; 120: e702-12.
  83. Bisgaard H, Zielen S, Garcia-Garcia M.L et al. Montelukast reduces asthma exacerbations in 2- to 5-year - old children with intermittent asthma. Am J Respir Crit Care Med 2005; 171: 315 22.
  84. Peng W.S, Chen X, Yang X.Y, Liu E.M. Systematic review of montelukast’s efficacy for preventing post - bronchiolitis wheezing. Pediatr Allergy Immunol 2014; 25 (2): 143-50.
  85. Matsuse H, Fukahori S, Tsuchida T et al. Effects of a short course of pranlukast combined with systemic corticosteroid on acute asthma exacerbation induced by upper respiratory tract infection. J Asthma 2012; 49 (6): 637-41.
  86. Matsuse H, Tsuchida T, Fukahori S et al. Retrospective cohort study of leukotriene receptor antagonist therapy for preventing upper respiratory infection - induced acute asthma exacerbations. Allergy Rhinol 2013; 4: 127-31.
  87. Venarske D.L, Busse W.W, Griffin M.R et al. The relationship of rhinovirus - associated asthma hospitalizations with inhaled corticosteroidsand smoking. J Infect Dis 2006; 193: 1536-43.
  88. Matsuse H, Kondo Y, Saeki S et al. Naturally occurring parainfluenza virus 3 infection in adults induces mild exacerbation of asthma associated with increased sputum concentrations of cysteinyl leukotrienes. Int Arch Allergy Immunol 2005; 138: 267-72.
  89. Dworski R, Fitzgerald G.A, Oates J.A, Sheller J.R. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 1994; 149: 953-9.
  90. Chaudhuri R, Livingston E, Mc Mahon D et al. Cigarette Smoking Impairs the Therapeutic Response to Oral Corticosteroids in Chronic Asthma. Am J Respir Crit Care Med 2003; 168: 1308-11.
  91. Peters-Golden M, Swern A, Bird S et al. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006; 27: 495-503.
  92. Dahlén S.E, Malmstróm K, Nizankowska E et al. Improvement of aspirin - intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double - blind, placebo - controlled trial. Am J Respir Crit Care Med 2002; 165: 9-14.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».